title: Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO).
abstract: OBJECTIVE
  The overall prognosis for recurrent malignant glioma (MG) is extremely poor, and treatment options are limited. We evaluated our multicenter retrospective experience for patients with recurrent MG administering bevacizumab and irinotecan in combination therapy.
  
  
  METHODS
  A total of 115 patients with grade IV glial tumor (n = 93) and grade III glial tumor (n = 22) were retrospectively evaluated at 14 centers in Turkey. Primary objectives of the study were to evaluate the efficacy and toxicity of the bevacizumab and irinotecan as salvage treatment based on response to therapy, progression-free survival (PFS), 6 months of PFS, overall survival (OS), and 6 months of OS (OS6).
  
  
  RESULTS
  Bevacizumab and irinotecan were performed as second line (79.1 %) and third line treatment (20.9 %). Median chemotherapy cycle was 6 (range 1-37), and median follow-up was 6 months (range 1-36 months). Objective response rate was 39.1 %. Six-month PFS and OS6 were 46.3 % and 67.5 %, respectively. Median PFS was 6 months (95 % CI 2.5-9.5) and 6 months (95 % CI 4.9-7.1) in the grade III and IV groups, respectively (p = 0.773). Median OS was 9 months (95 % CI 7.1-10.9) and 8 months (95 % CI 6.6-9.4) in the grade III and IV groups, respectively (p = 0.450). Serious toxicities were observed in 7.8 % of patients. Treatment-related toxic death was observed in 3 patients. There was no treatment related to central nervous system hemorrhage or other serious hemorrhages.
  
  
  CONCLUSIONS
  Present study results were consistent with previous studies. In addition, we detected similar outcomes in grade III and IV glial tumors.
authors: Department of Medical Oncology, Ataturk Training and Research Hospital, Bilkent, Ankara 0906800, Turkey. drumutdemirci@gmail.com
authors: Umut
authors: U
authors: Demirci
authors: Gulnihal
authors: G
authors: Tufan
authors: Bilge
authors: B
authors: Aktas
authors: Ozan
authors: O
authors: Balakan
authors: Ahmet
authors: A
authors: Alacacioglu
authors: Faysal
authors: F
authors: Dane
authors: Huseyin
authors: H
authors: Engin
authors: M Ali
authors: MA
authors: Kaplan
authors: Yusuf
authors: Y
authors: Gunaydin
authors: Nuriye Y
authors: NY
authors: Ozdemir
authors: I
authors: I
authors: Tugba Unek
authors: Halit
authors: H
authors: Karaca
authors: Tulay
authors: T
authors: Akman
authors: Ozlem U
authors: OU
authors: Sonmez
authors: Ugur
authors: U
authors: Coskun
authors: Hakan
authors: H
authors: Harputluoglu
authors: Alper
authors: A
authors: Sevinc
authors: Onder
authors: O
authors: Tonyali
authors: Suleyman
authors: S
authors: Buyukberber
authors: Mustafa
authors: M
authors: Benekli
mesh_terms: D000328:Adult; D000368:Aged; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives; D018450:Disease Progression; D005260:Female; D005500:Follow-Up Studies; D005910:Glioma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D012008:Recurrence; D012189:Retrospective Studies; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D000077146:Irinotecan; D002166:Camptothecin
references: J Clin Oncol. 1999 Aug;17(8):2572-8
references: 10561324
references: J Clin Oncol. 2009 Oct 1;27(28):4733-40
references: 19720927
references: J Clin Oncol. 2007 Oct 20;25(30):4722-9
references: 17947719
references: Expert Rev Anticancer Ther. 2011 Nov;11(11):1713-7
references: 22050020
references: Cancer Cell. 2012 Jul 10;22(1):21-35
references: 22789536
references: J Clin Oncol. 1990 Jul;8(7):1277-80
references: 2358840
references: BMC Cancer. 2010 Jun 02;10:252
references: 20525214
references: Neuro Oncol. 2009 Feb;11(1):80-91
references: 18784279
references: Acta Oncol. 2011 Jun;50(5):630-5
references: 21495907
references: Nat Rev Cancer. 2010 May;10(5):319-31
references: 20414201
references: Clin Cancer Res. 2003 Apr;9(4):1399-405
references: 12684411
references: Semin Oncol. 2003 Dec;30(6 Suppl 19):10-4
references: 14765378
references: J Neurooncol. 2001 Nov;55(2):91-100
references: 11817706
references: Anticancer Drugs. 2012 Jul;23(6):659-65
references: 22634799
references: Neuro Oncol. 2012 Nov;14 Suppl 5:v1-49
references: 23095881
references: Clin Cancer Res. 2008 Nov 1;14(21):7068-73
references: 18981004
references: Neurology. 2004 Oct 12;63(7):1281-4
references: 15477552
references: J Clin Oncol. 2010 Apr 10;28(11):1963-72
references: 20231676
references: Int Immunopharmacol. 2012 Dec;14(4):546-9
references: 22940539
references: J Clin Oncol. 1999 May;17(5):1516-25
references: 10334539
references: Neuro Oncol. 2012 May;14(5):667-73
references: 22492961
references: J Clin Oncol. 2009 Feb 10;27(5):740-5
references: 19114704
references: J Neurooncol. 2011 Sep;104(3):639-46
references: 21468776
references: Neuro Oncol. 2011 Jan;13(1):143-51
references: 21084434
references: J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
references: 10655437
references: Cancer. 2008 May 15;112(10):2267-73
references: 18327820
references: Br J Cancer. 2000 Sep;83(5):588-93
references: 10944597
references: J Neurooncol. 2008 Aug;89(1):113-8
references: 18438609
references: J Clin Oncol. 2010 Apr 20;28(12):e188-9; author reply e190-2
references: 20159801